La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Shanghai Henlius Biotech Gestion

Gestion contrôle des critères 2/4

Le PDG Shanghai Henlius Biotech's est Jason Zhu, nommé en Jul2023, a un mandat de 1.08 ans. La rémunération annuelle totale est CN¥ 9.26M, composée du salaire de 87.8% et des bonus 12.2%, y compris les actions et options de la société. détient directement 0.009% des actions de la société, d'une valeur de HK$ 1.15M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2 ans et 4.9 ans.

Informations clés

Jason Zhu

Directeur général

CN¥9.3m

Rémunération totale

Pourcentage du salaire du PDG	87.8%
Durée du mandat du directeur général	1.1yrs
Propriété du PDG	0.009%
Durée moyenne d'occupation des postes de direction	2yrs
Durée moyenne du mandat des membres du conseil d'administration	4.9yrs

Mises à jour récentes de la gestion

Recent updates

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

May 25

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 25

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Mar 10

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Dec 31

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Nov 25

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 18

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Aug 03

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

May 31

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Apr 06

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 22

Analyse de la rémunération des PDG

Comment la rémunération de Jason Zhu a-t-elle évolué par rapport aux bénéfices de Shanghai Henlius Biotech?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Dec 31 2023	CN¥9m	CN¥8m	CN¥546m

Rémunération vs marché: La rémunération totale de Jason ($USD 1.30M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 629.60K ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Jason avec les performances de l'entreprise.

PDG

Jason Zhu (45 yo)

1.1yrs

Titularisation

CN¥9,261,000

Compensation

Dr. Jun Zhu, also known as Jason, had been Chief Financial Officer at Shanghai Henlius Biotech, Inc. since May 1, 2023 until July 1, 2024 and served as its President since November 30, 2021 until October 1...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Wenjie Zhang	Executive Chairman of the Board	4.6yrs	CN¥12.58m	pas de données
Jun Zhu	CEO & Executive Director	1.1yrs	CN¥9.26m	0.0092% CN¥ 1.2m
Huang Wei	President	less than a year	pas de données	pas de données
Shi-Kau Liu	Co-founder & Head of Strategy Advisory Committee	14.5yrs	CN¥6.21m	0.44% CN¥ 55.6m
Wei-Dong Jiang	Co-Founder & Co-Head of Innovative Advisory Committee	14.5yrs	pas de données	0.13% CN¥ 16.6m
Yingbo Mao	VP & CFO	less than a year	pas de données	pas de données
Jifeng Zhang	CTO & Senior VP	1.7yrs	pas de données	pas de données
Miaojie Chen	Vice President of Legal & Compliance Department	1.6yrs	pas de données	pas de données
Wallis Zeng	VP of Sales & Oncology Business Unit	4.6yrs	pas de données	pas de données
Junhua Li	VP & Chief Human Resource Officer	2.3yrs	pas de données	pas de données
Xinjun Guo	Senior Vice President	no data	pas de données	pas de données
Kurt Yu	Senior VP & Chief Commercial Officer	3.6yrs	pas de données	pas de données

2.0yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 2696 est considérée comme expérimentée (ancienneté moyenne 2 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Wenjie Zhang	Executive Chairman of the Board	4.6yrs	CN¥12.58m	pas de données
Jun Zhu	CEO & Executive Director	less than a year	CN¥9.26m	0.0092% CN¥ 1.2m
Tak Young So	Independent Non-Executive Director	4.9yrs	CN¥258.00k	pas de données
Qiyu Chen	Non-Executive Director	11.6yrs	pas de données	pas de données
Guoping Zhao	Independent Non-Executive Director	4.9yrs	CN¥258.00k	pas de données
Xiaohui Guan	Non-Executive Director	5.7yrs	pas de données	pas de données
K. Christopher Garcia	Member of Scientific Advisory Board	1.1yrs	pas de données	pas de données
Yifang Wu	Non-Executive Director	9.2yrs	pas de données	pas de données
Deyong Wen	Non-Executive Director	2.1yrs	pas de données	pas de données
Lik Yuen Chan	Independent Non-Executive Director	4.9yrs	CN¥258.00k	pas de données
Ruilin Song	Independent Non-Executive Director	4.9yrs	CN¥258.00k	pas de données
Rongli Feng	Chairman of Supervisory Board	4.3yrs	pas de données	pas de données

4.9yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 2696 sont considérés comme expérimentés (ancienneté moyenne 4.9 ans).

Shanghai Henlius Biotech Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Shanghai Henlius Biotech, Inc. Announces Chief Financial Officer Changes

Less than half of directors are independent

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024

Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President

Shanghai Henlius Biotech, Inc. Announces Executive Appointments

Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee

Recent updates

Shanghai Henlius Biotech, Inc. to Report First Half, 2024 Results on Aug 26, 2024

Shanghai Henlius Biotech, Inc. Announces the First Patient Dose in A Phase 2 Clinical Trial of HLX53

Shanghai Henlius Biotech, Inc. Announces International Multicentre Phase 3 Clinical Trial for the First-Line Treatment of Metastatic Colorectal Cancer in Japan

Shanghai Henlius Biotech, Inc. Announces Chief Financial Officer Changes

Shanghai Henlius Biotech, Inc. Announces Completion of Phase 1 Clinical Study of a Biosimilar of Daratumumab HLX15 (Recombinant Anti-CD38 Human Monoclonal Antibody

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) agreed to acquire 78.3% stake in Shanghai Henlius Biotech, Inc. (SEHK:2696) from a group of shareholders for CNY 4.3 billion.

Investor sentiment improves as stock rises 19%

Less than half of directors are independent

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

National Medical Products Administration Approves Shanghai Henlius Biotech, Inc.'S the Supplemental Applications of Handayuan (Adalimumab Injection) for the New Indications

Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration (FDA)

Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024

Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration

New major risk - Financial position

Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection)

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Shanghai Henlius Biotech, Inc. Receives Approval from United States Food and Drug Administration for Application for Phase 1 Clinical Trial of HLX42 for Injection (Antibody-Drug Conjugate Targeting EGFR with Novel DNA Topoisomerase I Inhibitor)

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13

New minor risk - Financial position

Shanghai Henlius Biotech, Inc. to Report Nine Months, 2023 Results on Nov 15, 2023

Shanghai Henlius Biotech, Inc. Announces Shenzhen Nansiuzhuiang in Combination with Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Shanghai Henlius Biotech, Inc. Announces NMPA Approvals of Two ADC Candidates for IND

Shanghai Henlius Biotech, Inc. Announces the First Patient in Europe Has Been Dosed in the International Multi-Centre Phase 3 Clinical Trial

Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President

Shanghai Henlius Biotech, Inc. Announces the New Drug Application (Nda) for New Indication of Hansizhuang (Serplulimab Injection) an Innovative Anti-PD-1 Monoclonal Antibody

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. Announces Executive Appointments

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.47 loss in 1H 2022)

Shanghai Henlius Biotech, Inc. to Report Q2, 2023 Results on Aug 25, 2023

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee

Consensus EPS estimates fall by 31%

Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Financial Guidance for the Six Months Ended 30 June 2023

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Phase 2 Clinical Trial of HLX26

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

Shanghai Henlius Biotech, Inc. Announces Application for Phase 2 Clinical Trial of Hlx26

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Consensus revenue estimates increase by 13%

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces United States Food and Drug Administration Accepts the Biologic License Application for HLX02

Shanghai Henlius Biotech, Inc. Announces the First Patient in USA Has Been Dosed in Aninternational Multicentre Phase 3 Clinical Study Ofrecombinant Anti-Vegf Humanised Monoclonalantibody Ophthalmic Injection Hlx04-Ofor the Treatment of Wet Age-Related Maculardegeneration (Wamd)

Shanghai Henlius Biotech, Inc. Announces the Phase 1b/2 Clinical Trial of Hlx07

Shanghai Henlius Biotech, Inc. Announces Dosage of First Subject in Phase 1 Clinical Study of HLX15 (Recombinant Anti-CD38 Humanmonoclonal Antibody Injection) in Healthy Chinese Male Subjects

Shanghai Henlius Biotech, Inc. Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC

Shanghai Henlius Biotech Announces the First Patient Dosage in the United States of America in an International Multi-Centre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection)

Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in A Phase 1 Clinical Trialof Hlx60 (Recombinant Humanized Anti-Garp Monoclonalantibody Injection) in Combination with Hansizhuang(Serplulimab Injection) for the Treatment of Advanced Ormetastatic Solid Tumors in Australia

Shanghai Henlius Biotech, Inc. Doses First Patient in A Phase 1 Clinical Trial of anti-TIGIT Fc Fusion Protein HLX53 for the Treatment of advanced/Metastatic Solid Tumours or Lymphomasin Mainland China

Shanghai Henlius Biotech, Inc. Announces the First Patient Was Dosed in NCT05468489

Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Bridging Study Comparing Hansizhuang (Serplulimab Injection) Versus Atezolizumab

Shanghai Henlius Biotech, Inc. Announces Hansizhuang (Serplulimab Injection) in Combination with Chemotherapy and Concurrent Radiotherapy Approved to Commence A Phase 3 Clinical Trial

Less than half of directors are independent